Esophagus News

PHILADELPHIA — A once-weekly 360 mg dose of cendakimab sustained improvements in symptoms and endoscopic/histologic features of eosinophilic esophagitis at 48 weeks, according to data presented at the ACG Annual Scientific Meeting.

BOSTON — The odds for mortality, ventilation and septic shock among adults hospitalized with COPD went down if they also had GERD, according to data presented at the CHEST Annual Meeting.

Among patients with Barrett’s esophagus, every 5 kg/m2 increase in BMI was associated with up to a 6% relative increase in the risk for malignant progression, according to a systematic review and meta-analysis.

The biomarker-based Esopredict determined that patients with Barrett’s esophagus who were stratified as higher risk were 6.4-times more likely to progress to high-grade dysplasia or esophageal adenocarcinoma within 5 years, research showed.

“Aggressive” combination therapy for gastroesophageal reflux disease improved survival among patients with systemic sclerosis and interstitial lung disease, according to data published in Arthritis Research & Therapy.

Researchers found associations between Index of Severity for Eosinophilic Esophagitis scores and select clinical features across categories of disease severity, according to a study published in The Journal of Allergy and Clinical Immunology.

Treatment with Dupixent led to histologic remission at week 16 among a greater percentage of pediatric patients with eosinophilic esophagitis refractory to proton-pump inhibitor therapy compared with placebo, according to study results.

The FDA has expanded approval for Phathom Pharmaceuticals’ Voquezna tablets 10 mg to alleviate heartburn related in non-erosive gastroesophageal reflux disease, according to a company press release.

Targeted screening of older adults with GERD and a 5% probability of Barrett’s esophagus or esophageal adenocarcinoma could “substantially decrease” the population to screen, while still detecting more than 70% of disease, data showed.